Venture Capital firm, QVentures, has made a pre-seed fund investment into Presentient Technologies, a software platform developing innovative tools for companies running clinical trials. The funding round was led by QVentures with participation from Episode1 and industry angels.

Belfast-based cancer diagnostics company GenoME Diagnostics has closed a £1.4 million funding round with investment from QUBIS, the commercialisation arm of Queen’s University, Co-Fund NI (managed by Clarendon Fund Managers) and Deepbridge Capital.

Archangels-backed dental imaging technology company Calcivis is setting its sights on US growth having secured pre-market approval (PMA) from the US Food and Drug Administration (FDA).

CanSense - a Swansea company which has developed a blood test that aims to save lives by diagnosing bowel cancer at an early stage - has raised £1.5m from Mercia, the Development Bank of Wales and liquid biopsy company Nonacus.

CanSense’s test, which combines laser spectroscopy with artificial intelligence, is faster, less expensive and less invasive than a colonoscopy procedure and more acceptable for patients than a faecal blood detection kit. It could help detect bowel cancer at an early stage when it is much easier to treat and the chance of survival is much higher.

YFM has led a £10m investment into healthtech company DrDoctor along with Ananda Impact Ventures and 24 Haymarket

DrDoctor was founded in 2012 by Tom Whicher, Rinesh Amin and Perran Pengelly and provides digital care solutions to increase communication and engagement between patients and clinicians, managing 25 per cent of NHS outpatient appointments.

Innovative health app, Holly Health, marks a £1.5 million investment milestone with support from the Women Angels of the North angel syndicate and Leeds-based non-profit NorthInvest.  Promising better help for their 20,000-strong customer base. 

Cydar Medical, a global, cloud-based surgical software company, has completed a £9.3 million Series A funding round from investors including Pembroke VCT, Downing and Greenwood Way Capital.  

SPAIN: Innitius, the Spanish startup focused on improving diagnostics for women's health, has closed a €1.8 million financing round led by Clave Capital and Nara Capital in which most of the investors who had previously backed the company have also joined.  Created in 2017 and headquartered in Bilbao, Innitius aims to improve the health and quality of life of millions of pregnant women and newborns by reducing the impact of pathologies such as preterm birth, induction of birth or cervical cancer in our society.

Evonetix, the synthetic biology company bringing semiconductor technology to DNA synthesis, has completed a USD $24 million financing round, extending its total series B funding to over USD $54 million (circa GB £44 million). This fundraise was led by existing investor Foresite Capital, with Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence also participating in the round.

ITALY: MgShell, a MedTech that aims to revolutionise the treatment of exudative maculopathy, announces the closing of a €500,000 investment round by Bios Line Holding, a company that invests in Life Sciences ventures, Club degli Investitori, one of the leading business angel groups in Italy, and Italian Angels for Biotech, the first Italian angel association exclusively dedicated to Life Sciences. The latter made the investment through the Ersel Group’s Simon Fiduciaria.

Healistic, an innovative HealthTech mobile app and the first pharma-based speedy delivery service in the UK, has announced £1 million in pre-seed funding from leading international investors. 

Powered by the belief that healthcare should be effortless and immediately available to everyone, Healistic is building an all-in-one universal healthcare platform, providing a seamless experience in an asset-light marketplace business model.

EnsiliTech, the award-winning biopharmaceuticals company has raised £1.2 million in pre-seed funding to aid the development of a pioneering refrigeration-free approach to transporting vaccines and other materials.